Longevity News

The association between metabolic dysfunction-associated fatty liver disease and left ventricular mass index in patients with schizophrenia with long-term hospitalization

Source: Frontiers - Health • Published: 25 Aug 2026, 00:00

The association between metabolic dysfunction-associated fatty liver disease and left ventricular mass index in patients with schizophrenia with long-term hospitalization

Reports an analysis linking metabolic dysfunction-associated fatty liver disease to higher left ventricular mass index in long-term hospitalized schizophrenia patients.

Key Takeaways
  • MAFLD was identified in 231 cases (53.7%) of 430 long-term hospitalized patients with schizophrenia
  • Positive association between MAFLD and LVMI was found using Spearman correlation analysis (r=0.126, p=0.009)
  • Multivariate regression analysis revealed that after adjusting for age
Read Original Source

Continue exploring

Related longevity signals

Frontiers - HealthRevisiting macrophage metabolic reprogramming in metabolic dysfunction-associated steatotic liver disease: mechanisms, regulation, and therapeutic breakthroughsMacrophage metabolic reprogramming in fatty liver disease — a review article guiding readers through mechanisms, regulatory circuits, and therapeutic research directions.Frontiers - HealthGastrointestinal microbiota alterations associated with pediatric gastroesophageal reflux disease and proton pump inhibitor exposure: a systematic review of microbiome changes, dysbiosis markers, and associated clinical outcomesA systematic review synthesizes evidence linking pediatric gastroesophageal reflux and proton pump inhibitor exposure to gastrointestinal microbiota changes across aerodigestive compartments.Longevity TechnologyAltimmune starts Phase 3 testing for fatty liver treatmentA biotech update on the start of late-stage clinical testing for a metabolic liver therapy, previewing trial aims and development context.Frontiers - HealthNeutrophil percentage-to-albumin ratio is associated with low muscle mass risk in rheumatoid arthritis: evidence from a hospital-based cohort and NHANES validationAn observational analysis linking a composite inflammation and nutrition biomarker to low muscle mass risk in rheumatoid arthritis patients and population validation.